Skip to main content
Erschienen in: Wiener klinische Wochenschrift 9-10/2015

01.05.2015 | case report

Merkel cell carcinoma of the lower leg with retroperitoneal GIST: a very rare association

verfasst von: Uwe Wollina, MD, Gesina Hansel, MD, Felicitas Zimmermann, MD, Jacqueline Schönlebe, MD, Andreas Nowak, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 9-10/2015

Einloggen, um Zugang zu erhalten

Summary

Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin. Although its association with other malignancies is well known, an association with gastrointestinal stromal tumor (GIST) has yet not been described.
We report about a 65-year-old female patient who presented with a hypervascularized subcutaneous tumor mass of her left calf. Resection of the primary tumor and histopathological investigations confirmed the diagnosis of MCC. The patient was treated by delayed Mohs surgery, and tumor-free margins were obtained. Sentinel lymph node biopsy was negative for metastatic spread. Primary tumor and lymph node basin were treated by adjuvant radiotherapy. During staging of the patient, a second malignancy—a GIST—was detected. Neoadjuvant treatment with multikinase inhibitor imatinib induced a partial response of GIST that was eventually removed by surgery. However, 8 months later, the patient developed subcutaneous regional metastases of MCC, which were surgically removed. Adjuvant therapy was planned by oncologists.
To the best of our knowledge, the occurrence of MCC and GIST in the same patient has yet not been reported. In contrast to GIST, MCC did not respond to imatinib, although c-kit mutations are common in MCC.
Literatur
2.
Zurück zum Zitat Cardoso JC, Teixeira V, Tchernev G, Wollina U. Merkel cell carcinoma: a review and update on aetiopathogenesis, diagnosis and treatment approaches. Wien Med Wochenschr. 2013;163(15–16):359–67.CrossRefPubMed Cardoso JC, Teixeira V, Tchernev G, Wollina U. Merkel cell carcinoma: a review and update on aetiopathogenesis, diagnosis and treatment approaches. Wien Med Wochenschr. 2013;163(15–16):359–67.CrossRefPubMed
3.
Zurück zum Zitat Hohaus K, Köstler E, Schönlebe J, Klemm E, Wollina U. Merkel cell carcinoma—a retrospective analysis of 17 cases. J Eur Acad Dermatol Venereol. 2003;17(1):20–4.CrossRefPubMed Hohaus K, Köstler E, Schönlebe J, Klemm E, Wollina U. Merkel cell carcinoma—a retrospective analysis of 17 cases. J Eur Acad Dermatol Venereol. 2003;17(1):20–4.CrossRefPubMed
4.
Zurück zum Zitat Masterson L, Thibodeau BJ, Fortier LE, et al. Gene expression differences predict treatment outcome of Merkel cell carcinoma patients. J Skin Cancer. 2014;2014:596459.CrossRefPubMedCentralPubMed Masterson L, Thibodeau BJ, Fortier LE, et al. Gene expression differences predict treatment outcome of Merkel cell carcinoma patients. J Skin Cancer. 2014;2014:596459.CrossRefPubMedCentralPubMed
5.
6.
Zurück zum Zitat Garneski KM, Warcola AH, Feng Q, Kiviat NB, Leonard JH, Nghiem P. Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol. 2009;129(1):246–8.CrossRefPubMedCentralPubMed Garneski KM, Warcola AH, Feng Q, Kiviat NB, Leonard JH, Nghiem P. Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol. 2009;129(1):246–8.CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Kaae J, Hansen AV, Biggar RJ, et al. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst. 2010;102(11):793–801.CrossRefPubMed Kaae J, Hansen AV, Biggar RJ, et al. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst. 2010;102(11):793–801.CrossRefPubMed
8.
Zurück zum Zitat Howle JR, Hughes TM, Gebski V, Veness MJ. Merkel cell carcinoma: an Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients. J Am Acad Dermatol. 2012;67(1):33–40.CrossRefPubMed Howle JR, Hughes TM, Gebski V, Veness MJ. Merkel cell carcinoma: an Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients. J Am Acad Dermatol. 2012;67(1):33–40.CrossRefPubMed
9.
Zurück zum Zitat Shibayama Y, Imafuku S, Takahashi A, Nakayama J. Role of sentinel lymph node biopsy in patients with Merkel cell carcinoma: statistical analysis of 403 reported cases. Int J Clin Oncol. 2014. Epub ahead of print. Shibayama Y, Imafuku S, Takahashi A, Nakayama J. Role of sentinel lymph node biopsy in patients with Merkel cell carcinoma: statistical analysis of 403 reported cases. Int J Clin Oncol. 2014. Epub ahead of print.
10.
Zurück zum Zitat Cirillo F. Neuroendocrine tumors and their association with rare tumors: observation of 4 cases. Eur Rev Med Pharmacol Sci. 2010;14(7):577–88.PubMed Cirillo F. Neuroendocrine tumors and their association with rare tumors: observation of 4 cases. Eur Rev Med Pharmacol Sci. 2010;14(7):577–88.PubMed
11.
Zurück zum Zitat Lee CH, Liang CW, Espinosa I. The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology-the GIST of it. Adv Anat Pathol. 2010;17(3):222–32.CrossRefPubMed Lee CH, Liang CW, Espinosa I. The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology-the GIST of it. Adv Anat Pathol. 2010;17(3):222–32.CrossRefPubMed
12.
Zurück zum Zitat Sadeghi R, Adinehpoor Z, Maleki M, Fallahi B, Giovanella L, Treglia G. Prognostic significance of sentinel lymph node mapping in Merkel cell carcinoma: systematic review and meta-analysis of prognostic studies. Biomed Res Int. 2014;2014:489536.CrossRefPubMedCentralPubMed Sadeghi R, Adinehpoor Z, Maleki M, Fallahi B, Giovanella L, Treglia G. Prognostic significance of sentinel lymph node mapping in Merkel cell carcinoma: systematic review and meta-analysis of prognostic studies. Biomed Res Int. 2014;2014:489536.CrossRefPubMedCentralPubMed
13.
14.
Zurück zum Zitat Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626–32.CrossRefPubMed Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626–32.CrossRefPubMed
16.
Zurück zum Zitat Loader DE, Feldmann R, Baumgartner M, et al. Clinical remission of Merkel cell carcinoma after treatment with imatinib. J Am Acad Dermatol. 2013;69(4):e181–3.CrossRefPubMed Loader DE, Feldmann R, Baumgartner M, et al. Clinical remission of Merkel cell carcinoma after treatment with imatinib. J Am Acad Dermatol. 2013;69(4):e181–3.CrossRefPubMed
17.
Zurück zum Zitat Peuvrel L, Quereux G, Brocard A, Renaut JJ, Dréno B. Treatment of a multicentric Merkel cell carcinoma using imatinib. Eur J Dermatol. 2011;21(6):1009–10.PubMed Peuvrel L, Quereux G, Brocard A, Renaut JJ, Dréno B. Treatment of a multicentric Merkel cell carcinoma using imatinib. Eur J Dermatol. 2011;21(6):1009–10.PubMed
Metadaten
Titel
Merkel cell carcinoma of the lower leg with retroperitoneal GIST: a very rare association
verfasst von
Uwe Wollina, MD
Gesina Hansel, MD
Felicitas Zimmermann, MD
Jacqueline Schönlebe, MD
Andreas Nowak, MD
Publikationsdatum
01.05.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 9-10/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0660-z

Weitere Artikel der Ausgabe 9-10/2015

Wiener klinische Wochenschrift 9-10/2015 Zur Ausgabe

MUW researcher of the month

Researcher of the month